- Home
- IMOS vs MNMD Comparison
IMOS vs MNMD Comparison
Compare IMOS & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMOS
- MNMD
- Stock Information
- Founded
- IMOS 1997
- MNMD 2019
- Country
- IMOS Taiwan
- MNMD United States
- Employees
- IMOS N/A
- MNMD N/A
- Industry
- IMOS Semiconductors
- MNMD Pharmaceuticals and Biotechnology
- Sector
- IMOS Technology
- MNMD Health Care
- Exchange
- IMOS Nasdaq
- MNMD Nasdaq
- Market Cap
- IMOS 630.6M
- MNMD 509.2M
- IPO Year
- IMOS N/A
- MNMD N/A
- Fundamental
- Price
- IMOS $17.04
- MNMD $9.21
- Analyst Decision
- IMOS
- MNMD Strong Buy
- Analyst Count
- IMOS 0
- MNMD 6
- Target Price
- IMOS N/A
- MNMD $24.67
- AVG Volume (30 Days)
- IMOS 17.2K
- MNMD 1.2M
- Earning Date
- IMOS 08-12-2025
- MNMD 07-31-2025
- Dividend Yield
- IMOS 3.69%
- MNMD N/A
- EPS Growth
- IMOS N/A
- MNMD N/A
- EPS
- IMOS 0.05
- MNMD N/A
- Revenue
- IMOS $685,506,006.00
- MNMD N/A
- Revenue This Year
- IMOS $3.12
- MNMD N/A
- Revenue Next Year
- IMOS $3.25
- MNMD N/A
- P/E Ratio
- IMOS $18.42
- MNMD N/A
- Revenue Growth
- IMOS 2.89
- MNMD N/A
- 52 Week Low
- IMOS $12.78
- MNMD $4.70
- 52 Week High
- IMOS $24.41
- MNMD $10.44
- Technical
- Relative Strength Index (RSI)
- IMOS 38.56
- MNMD 60.11
- Support Level
- IMOS $16.87
- MNMD $8.94
- Resistance Level
- IMOS $18.32
- MNMD $10.09
- Average True Range (ATR)
- IMOS 0.41
- MNMD 0.48
- MACD
- IMOS -0.11
- MNMD -0.02
- Stochastic Oscillator
- IMOS 8.90
- MNMD 52.74
About IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).